We are international
Donate
• about myeloma TEXT SIZE   
Ask Dr Durie

ask_dr_durie_banner

 

Have a question? Submit it to AskDrDurie@myeloma.org!
 

facebook
googleplus
twitter
youtube


IMF Chairman and Co-Founder Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to askdrdurie@myeloma.org! For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at infoline@myeloma.org.

Our archives are brimming with useful information directed at - and asked by - patients, caregivers, and other interested parties... so please watch the episodes below, and share them as much as possible so that others may benefit!


 

 

 

#Ask Dr. Durie
    next      view all

09.22.16   How is the overall myeloma protein level in the blood affected by its distribution within and out of the body?

In this video, Dr. Durie discusses if myeloma proteins that leak out into the tissues impact the protein level in the blood.

BOTTOM LINE:

Be patient when considering myeloma protein levels. 


09.15.16   Is major surgery on a blood clot in my leg safe?

In this week’s video, Dr. Brian Durie addresses a myeloma patient’s concerns about having  femeropopliteal bypass graft surgery.

BOTTOM LINE:

Surgery for a myeloma patient should be approached in the same fashion as it would be for any other patient.


09.08.16   How do Revlimid® and dexamethasone work together against myeloma?

In this week’s video, Dr. Brian Durie addresses a patient’s concern about continued use of dexamethasone with Rev/dex combination therapy.

BOTTOM LINE:

Rev/dex is great for initial therapy, but for maintenance, it may be best to use just Revlimid.


09.01.16   What is CRISPR?

In this week's video, Dr. Brian Durie explains a molecular "editing" technique and how it applies to myeloma.

BOTTOM LINE:

The CRISPR technique is a promising, yet developing technology for the treatment of myeloma.


08.25.16   What is iStopMM?

In this week’s video, Dr. Brian Durie shares the objectives and process for the new iStopMM project.

BOTTOM LINE: 

The iStopMM project has the potential to cure or prevent myeloma for all of Iceland.


08.18.16   Should I change treatment regimens if my IgG myeloma protein has spiked?

In this week’s video, Dr. Durie addresses a concerned patient’s question about lab test results. 

BOTTOM LINE:

If test results seem inaccurate, get them double-checked.


08.11.16   Should a patient in long-term remission with light-chain levels increasing, be treated?

In this week’s video, Dr. Brian Durie recommends how a patient should be monitored if his light chain level is increasing.

BOTTOM LINE:

Assess the myeloma status before making radical treatment changes.


08.04.16   What should be done to carefully monitor myeloma in the remission phase?

In this week’s video, Dr. Durie addresses a patient’s concerns about different recommendations she has received about monitoring her disease.

BOTTOM LINE:

Patients in remission must have their myeloma monitored regularly and see their GP or internist.

 


07.28.16   How important is the new IMWG response criteria, which includes the use of minimal residual disease testing?

In this week’s video, Dr. Brian Durie explains why MRD testing is important for assessing the results of clinical trials, but is not yet ready for the clinic.

BOTTOM LINE:

In clinical trials, the new criteria are essential to assess new drug combination therapies.


07.21.16   Even though the kappa level is normal, the lambda level—the other normal light-chain—why is it also low?

In this video, Dr. Durie discusses why slight reductions in lambda levels in MM patients are not necessarily cause for alarm.

BOTTOM LINE:

Because the kappa, the myeloma light chain, is still in the normal range, the disease is in remission.


    next      view all